Quick Takeaways:
- Elanco has completed a 25,000-square-foot expansion of its Elwood, Kansas manufacturing facility, strengthening production capacity for monoclonal antibody (mAb) therapies and supporting the company’s next-generation animal health pipeline.
- The $120 million investment increases manufacturing capacity more than fourfold and adds upstream and downstream processing equipment, a pilot plant for process development, a quality control laboratory and additional support space. Another $30 million investment in warehousing is planned through 2028.
- The expanded facility currently manufactures Befrena (tirnovetmab) for canine allergic and atopic dermatitis and Trutect, the first and only approved therapeutic solution for canine parvovirus. Elanco said demand for Befrena is running at twice expectations, with expanded capacity expected to reach unconstrained levels in early 2027.
Why It Matters?
Elanco’s $120M expansion of its Elwood, Kansas site quadruples monoclonal antibody capacity and adds upstream/downstream processing, a pilot plant and QC lab, directly supporting its new biologics franchise (Befrena for canine atopic dermatitis and Trutect for canine parvovirus) and de‑risking supply as demand for Befrena runs at ~2× expectations. 1166 With another $30M planned for warehousing through 2028, Elanco is positioning Elwood as a scalable biologics hub to accelerate its next‑gen pet therapeutics pipeline and capture share in the fast‑growing veterinary mAb market
Source: PRnewswire
